ClinicalTrials.gg
RecruitingNCT07176312ZANGEAUpdated Jun 30, 2026

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

A Phase 2 interventional study of Zanidatamab and Pembrolizumab in Gastroesophageal Adenocarcinoma, First Line Therapy and HER2 + Gastric Cancer, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 20 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Stomach Neoplasms with a site in Germany — 26 open to participants now, 42 under way, 13 of them phase 3. Stomach Neoplasms · Germany.

Planned enrollment
92nd of 138
80 · median 181
Started
2026
with 5 others
Phase 2
50 of 162
4 open now
Primary completion
2029-03
later than 33 of 41 live
Registered
156th of 162
by date
Lead sponsor
8 of 162
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 162 studies in Stomach Neoplasms with a site in Germany, this one is the 92nd largest by planned enrollment of the 138 interventional ones that give a count, is one of 6 that started in 2026, is one of 50 in phase 2, reaches primary completion later than 33 of the 41 other live ones, and was the 156th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

26 of the 162 studies in Stomach Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Stomach Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.

Read the detailed description

The ZANGEA trial is designed as a single arm phase II study, which aims to estimate the therapeutic efficacy of the experimental regimen zanidatamab in combination with pembrolizumab and chemotherapy in HER2 and PD-L1 positive metastatic gastroesophageal adenocarcinoma (GEA) without previous palliative treatment.The primary objective is to evaluate the efficacy of this treatment, secondary objectives are to further determine the efficacy, to evaluate safety and tolerability and to assess quality of life (QoL).

In addition, two explorative objectives are defined: preplanned matched-pair analyses comparing the study arm to a historical study arm with trastuzumab, chemotherapy and PD-1 inhibitor (AIO INTEGA) in terms of efficacy, tolerability, and translational data and to correlate analysis between selected molecular tumor, serum and microbiome parameters and clinical data to identify molecular biomarkers predictive for tumor response, toxicity, and survival.

A total of 80 patients will be enrolled in approx. 30 study sites in Germany and Austria.

03

Conditions studied

  • Gastroesophageal Adenocarcinoma
  • First Line Therapy
  • HER2 + Gastric Cancer
  • PDL-1
  • Metastases

Keywords

  • GEA
  • Gastroesophageal adenocarcinoma
  • first line therapy
  • HER2-positive
  • PD-L1 positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient* has signed and dated a written form in accordance with regulatory and institutional guidelines and approved by an institutional Review Board / Independent Ethics Committee. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
  • Patient is, in the investigator's judgement, willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.
  • Patient is ≥ 18 years of age at time of signing the written informed consent.
  • Patient has been diagnosed with confirmed unresectable advanced/ -positive (defined as IHC 3+ or IHC 2+ with ISH+) and -positive (combined positive score CPS ≥ 1) gastroesophageal adenocarcinoma per local standard assessment of new or . Results of local HER2 and PD-L1 assessment will be retrospectively confirmed by central pathological re-assessment.

Note: In case of metachronous metastases, particularly in case of prior treatment with PD-(L)1-antibodies, a fresh re-biopsy should be performed for immunohistochemistry testing (local pathology), if feasible.

  • Patient has assessable disease (measurable or non-measurable) per v1.1.
  • Patient did not receive previous palliative treatment. Prior or neoadjuvant chemotherapy, immunotherapy, radiotherapy and/or chemoradiotherapy (but not anti HER2-targeted treatment) are permitted as long as the last administration of the last regimen (whichever was given last) occurred at least 6 months prior to enrolment.
  • Patient has performance status ≤ 1.
  • Patient has adequate hepatic, renal and hematologic functions:

    1. Absolute number of neutrophils (ANC) ≥ 1.5 x 10\^9/L
    2. ≥ 100x10\^3/µL
    3. Serum creatinine ≤ 1.5 x or (measured by 24 h urine) ≥ 30 mL/min (i.e., if serum creatinine level is > 1.5 x upper limit of normal (ULN), then a 24-hour urine test must be performed to check the creatinine clearance to be determined.
    4. (SGOT) and ALT (SGPT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present)
    5. Total ≤ 1.5 x ULN (or \< 3.0 x ULN in case of prior liver involvement or Gilbert's Syndrome)
  • Patient has adequate coagulation function as defined by (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).
  • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotrophin [hCG]) within 7 days prior to the start of study drug. Women must not be breastfeeding. WOCBP must use a highly effective method(s) of during the treatment period and for 4 months after last dose of zanidatamab and/or pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. Males who are sexually active with WOCBP must agree to remain abstinent or follow instructions for method(s) of contraception during the treatment and for 4 months after the last dose of zanidatamab and/or pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. In addition, male subjects must be willing to refrain from sperm donation during this time.

    • There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.

Exclusion criteria

Exclusion Criteria:

  • Patient has any known including allergy or to the trial drugs or any constituent of the products as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies.
  • Patient received prior anti -targeted treatment for GEA.
  • Patient has other than the disease under study within 5 years prior to inclusion, except for those with a negligible risk of or death (e.g., expected 5-year OS > 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent).
  • Patient has untreated known . Patient is eligible, if previous CNS metastases are adequately treated and patient has neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for ≥ 2 weeks prior to enrolment, and did not receive , or is on a stable or decreasing dose of \< 10 mg daily prednisone (or equivalent) for ≥ 2 weeks prior to inclusion.
  • Patient has abnormal baseline (LVEF \< 50 %), assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI) scan.
  • Patient has active, known, or suspected disease. Exception: Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended that the medical expert/sponsor be consulted prior to signing .
  • Patient has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other medications within 14 days of trial drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Patient has persisting toxicity related to prior therapy ( v.5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  • Patient has any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with trial participation, trial drug administration, or would impair the ability of the patient to receive trial drug.
  • Patient has significant acute or chronic infections including, among others:
  • Any positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Any positive test result for virus or virus indicating acute or chronic infection.
  • Patient has history of allogeneic tissue / solid organ transplant.
  • Patient has been incarcerated or involuntarily institutionalized by court order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG].
  • Patient is unable to consent because he/she does not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
  • Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the trial medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of trial results.
  • Patient currently participates in any other interventional clinical study within 30 days before the first administration of the product or at any time during the trial, unless it is an observational (non-interventional) study, or during the follow-up period of an interventional study with last dose of investigational product ≥28 days prior to enrolment in this trial.
  • Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity or use of any medications known to inhibit DPD (including brivudine, sorivudine and analogs) within 4 weeks prior to enrolment.
  • Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of must have a negative serum pregnancy test result within 7 days prior to initiation of trial treatment.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Zanidatamab plus pembrolizumab and mFOLFOX

    Single Arm with Zanidatamab Q2W in combination with pembrolizumab Q6W and mFOLFOX Q2W

    Drug: Zanidatamab · Drug: Pembrolizumab · Drug: mFOLFOX

Interventions

  • Zanidatamab 1,200 mg (patients \<70 kg at baseline) or 1,600 mg (patients ≥70 kg at baseline), administered i.v. on day 1 of each 2-week cycle (Q2W)

  • Pembrolizumab 400 mg, administered i.v. on day 1 of every third cycle (Q6W)

  • DrugmFOLFOX

    modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and 2 of each 2-week cycle (Q2W)

06

What researchers measure

Primary outcomes

  1. Efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in previously untreated HER2 and PD-L1 positive metastatic gastroesophageal adenocarcinoma (GEA)

    Progression-free survival rate at 12 months (PFS@12), estimated using Kaplan Meier method and defined as proportion of patients alive and progression-free 12 months after start of trial medication

    Time frame: 12 months after start of trial medication

Secondary outcomes

  1. To further determine the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in metastatic GEA.

    Overall response rate (ORR), defined as proportion of patients achieving complete or partial response (CR/PR) acc. to RECIST v1.1. Disease control rate (DCR), defined as proportion of patients achieving CR, PR, or stable disease (SD) acc. to RECIST v1.1. Duration of response (DoR), defined as time from response initiation (when either CR or PR is first determined) to disease progression acc. to RECIST v1.1 or death due to any cause. Progression-free survival (PFS), defined as time from first treatment until date of progression acc. to RECIST v1.1 or death due to any cause. Overall survival (OS), defined as time from first treatment until date of death due to any cause.

    Time frame: up to 42 months after enrolment

  2. To evaluate safety and tolerability of zanidatamab in combination with pembrolizumab and chemotherapy in metastatic GEA.

    Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing, and severity of adverse events using NCI CTCAE v5.0

    Time frame: up to 25 months after first study treatment

  3. Assessment of quality of life (QoL) data

    Assessment of QoL during treatment and follow-up using EORTC QLQ-C30 and EQ-5D-5L questionnaires.

    Time frame: up to 42 months after first study treatment

Other outcomes

  1. Preplanned matched-pair analyses comparing the study arm to a historical study arm

    Preplanned matched-pair analyses comparing the study arm to a historical study arm with trastuzumab, chemotherapy and PD-1 inhibitor (AIO INTEGA) in terms of efficacy, tolerability, and translational data

    Time frame: after end of study of all patients, up to 54 months after first patient enrolment

  2. correlation analysis between selected molecular tumor, serum and microbiome parameters and clinical data to identify molecular biomarkers predictive for tumor response, toxicity, and survival.

    To correlate analysis between selected molecular tumor (such as CPS cut-offs ≤ 5 and \>5 - 10, as well as HER2 IHC2+/ISH+ vs. IHC3+), serum and microbiome parameters and clinical data to identify molecular biomarkers predictive for tumor response, toxicity, and survival.

    Time frame: after end of study of all patients, up to 54 months after first patient enrolment

07

Study locations

14 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 38 months after the start.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 38 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 16, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176312
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Jan 16, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 30, 2026

Study contacts

Alexander Stein, Prof. Dr.
Contact
stein@hope-hamburg.de
+49 (0) 40 36035220
Clara Dreyling, Dr.
Contact
dreyling.clara@ikf-khnw.de
+49 (0)69 5899 787 31
Salah-Eddin Al-Batran, Prof. Dr.
study director · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Alexander Stein, Prof. Dr.
principal investigator · Hämatologisch-Onkologische Praxis Eppendorf University Cancer Center Hamburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanidatamab

Start the discussion